Phase 1 Studies of Sirolimus Alone or in Combination with Pharmacokinetic Modulators in Advanced Cancer Patients

PURPOSE: Sirolimus is the eponymous inhibitor of the mammalian target of rapamycin (mTOR); however, only its analogues have been approved as cancer therapies. Nevertheless, sirolimus is readily available, has been well-studied in organ transplant patients, and demonstrates efficacy in several precli...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Clin Cancer Res
Autors principals: Cohen, Ezra EW, Wu, Kehua, Hartford, Christine, Kocherginsky, Masha, Eaton, Kimberly Napoli, Zha, Yuanyuan, Nallari, Anitha, Maitland, Michael L, Fox-Kay, Kammi, Moshier, Kristin, House, Larry, Ramirez, Jacqueline, Undevia, Samir D, Fleming, Gini F, Gajewski, Thomas F, Ratain, Mark J
Format: Artigo
Idioma:Inglês
Publicat: 2012
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4410974/
https://ncbi.nlm.nih.gov/pubmed/22872575
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-12-0110
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars